US IPO Lays Into EU Plans To Cut Data Protection & Extend ‘Bolar’ Exemption

 
• By Ian Schofield

The IPO says some provisions in the EU pharma revision could contravene the TRIPS agreement, including plans to suspend regulatory data protection on products subject to a compulsory licence in times of health emergencies.

Problems
The EU pharma review is throwing up a lot of questions • Source: Shutterstock

More from Europe

More from Geography